Vertex Pharmaceuticals Incorporated (VRTX) |
|
270.635 2.905 (1.09%)
|
09-29 09:53 |
|
Open: |
267.82 |
Pre. Close: |
267.73 |
|
High:
|
270.809 |
Low:
|
266.49 |
|
Volume:
|
82,326 |
Market Cap:
|
70,491M |
|
|
|
|
Vertex Pharmaceuticals, Inc. engages in the business of discovering, developing, manufacturing and commercializing small molecule drugs for patients with serious diseases. The company is headquartered in Boston, Massachusetts and currently employs 2,500 full-time employees. The firm is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications. The firm's marketed medicines are ORKAMBI and KALYDECO. ORKAMBI (lumacaftor in combination with ivacaftor) is approved as a treatment for patients having two copies (homozygous) of the Delta-F508 (F508del) mutation in their cystic fibrosis transmembrane conductance regulator (CFTR) gene. KALYDECO (ivacaftor) is approved for the treatment of CF patients having the G551D mutation or other specified mutations in their CFTR gene. The firm's development programs in the field of CF include Tezacaftor (VX-661), VX-152, VX-440, VX-659, VX-445 and VX-371. VX-152, VX-440, VX-659 and VX-445 are CFTR corrector compounds. |
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
270.924 - 272.24 |
272.24 - 273.537 |
|
Low:
|
260.346 - 262 |
262 - 263.63 |
|
Close:
|
264.643 - 267.286 |
267.286 - 269.891 |
|
Technical analysis |
as of: 2020-09-28 4:38:46 PM |
|
Overall:
|
 |
| Stoxline posted a BUY today, same as yesterday. Upward movement continues. |
| Target: |
Six months: 317.92 One year: 331.07 |
| Support: |
Support1: 253.97 Support2: 211.30 |
| Resistance: |
Resistance1: 272.19 Resistance2: 283.45 |
| Pivot: |
264.38  |
| Moving Average: |
MA(5): 266.09 MA(20): 266.81 
MA(100): 277.51 MA(250): 244.81 |
| MACD: |
MACD(12,26): -1.62 Signal(9): -2.26 |
| Stochastic oscillator: |
%K(14,3): 58.47 %D(3): 47.39 |
| RSI: |
RSI(14): 49.71 |
| 52-week: |
High: 306.08 Low: 165.23 Change(%): 59.8 |
| Average Vol(K): |
3-Month: 128700 10-Days: 131934 |
|
Price, moving averages and Bollinger Bands |
|
Price and moving averages has closed above its Short term moving average. Short term moving average is currently below mid-term; AND below long term moving averages. From the relationship between price and moving averages; we can see that: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.VRTX has closed below upper band by 29.8%. Bollinger Bands are 38.4% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Headline News |
Mon, 28 Sep 2020
Analysts Mean recommendation for Vertex Pharmaceuticals Incorporated (VRTX) was 2.00: Is this the key time? - The InvestChronicle
Mon, 28 Sep 2020
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) on the Path to Profitability - The Oracle Dispatch
Mon, 28 Sep 2020
Zacks: Analysts Expect Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) to Post $2.29 EPS - MarketBeat
Fri, 25 Sep 2020
Vertex Pharmaceuticals (NASDAQ:VRTX) Upgraded to Sell by BidaskClub - MarketBeat
Tue, 15 Sep 2020
Boiling and ready to burst as Vertex Pharmaceuticals Incorporated (VRTX) last month performance was -0.88% - The InvestChronicle
Fri, 11 Sep 2020
Vertex Pharmaceuticals (VRTX) Outpaces Stock Market Gains: What You Should Know - Nasdaq
|
Financial Analysis |
| Growth |
 |
| Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing. |
| Profitability |
|
| Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs. |
| Solvency |
 |
| Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry. |
| Efficiency |
 |
| Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not. |
| Price to Book Value: |
Outperform |
Discounted cash flow: |
Outperform |
| Return on Assets: |
Neutral |
Price to Earnings: |
Outperform |
| Return on Equity: |
Outperform |
Debt to Equity: |
Neutral |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. (M) |
260 |
| Shares Float (M) |
260 |
|
% Held by Insiders
|
0.14 |
|
% Held by Institutions
|
97.83 |
|
Shares Short (K)
|
3,350 |
|
Shares Short P. Month (K)
|
3,360 |
Stock Financials |
|
EPS
|
7.920 |
|
EPS Est This Year
|
1.630 |
|
EPS Est Next Year
|
2.890 |
|
Book Value (p.s.)
|
28.910 |
|
Profit Margin
|
38.51 |
|
Operating Margin
|
38.95 |
|
Return on Assets (ttm)
|
15.3 |
|
Return on Equity (ttm)
|
33.1 |
|
Qtrly Rev. Growth
|
62.0 |
|
Gross Profit (p.s.)
|
7.141 |
|
Sales Per Share
|
20.732 |
|
EBITDA (p.s.)
|
8.485 |
|
Qtrly Earnings Growth
|
213.10 |
|
Operating Cash Flow (M)
|
2,640 |
|
Levered Free Cash Flow (M)
|
1,820 |
Stock Valuations |
|
PE Ratio
|
33.80 |
|
PEG Ratio
|
0.41 |
|
Price to Book value
|
9.26 |
|
Price to Sales
|
12.91 |
|
Price to Cash Flow
|
26.42 |
Stock Dividends |
|
Dividend
|
|
|
Forward Dividend
|
|
|
Dividend Yield
|
|
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
7 Binary Options
|
|
Your Ad Here
|
|
